Research use only — not FDA-cleared, not medical advice. Always consult FDA-approved labeling and a qualified clinician.

CIViC Variants/Amplification

Amplification

CIViC ID: 270 · Gene: MET

Variant Summary

HGVS: —
Variant Type(s): transcript_amplification
Evidence Items: 12

Evidence Level Distribution

Level C: 10Level D: 2

Evidence Items

Showing CIViC evidence rows where gene = MET and variant = Amplification.

Level	Type	Direction	Significance	Disease	Drugs	Rating
D	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Crizotinib	4
C	Predictive	Supports	Sensitivity/Response	Colorectal Cancer	Crizotinib,Vemurafenib	4
D	Predictive	Supports	Resistance	Lung Non-small Cell Carcinoma	Gefitinib	4
C	Predictive	Supports	Sensitivity/Response	Glioblastoma	Crizotinib	3
C	Predictive	Supports	Sensitivity/Response	Lung Adenocarcinoma	Crizotinib	3
C	Predictive	Supports	Sensitivity/Response	Cancer	Crizotinib	3
C	Predictive	Supports	Sensitivity/Response	Gastric Adenocarcinoma	Onartuzumab	3
C	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Crizotinib	3
C	Predictive	Supports	Resistance	Lung Adenocarcinoma	Erlotinib,Gefitinib	2
C	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Crizotinib	2
C	Predictive	Supports	Sensitivity/Response	Lung Adenocarcinoma	Crizotinib	2
C	Predictive	Supports	Sensitivity/Response	Lung Squamous Cell Carcinoma	Crizotinib	2